Bladder Cancer News

Avelumab Immunotherapy Approved for Bladder Cancer (May 15, 2017)

Bavencio (Avelumab), a programmed cell death ligand–1 (PD L1) inhibitor, has been approved for treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease progressed during or following platinum-containing chemotherapy... Continue Reading

FDA Approves Imfinzi for Treatment of Urothelial Cancer (May 11, 2017)

The US Food and Drug Administration (FDA) today granted accelerated approval to Imfinzi (durvalumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing... Continue Reading

FDA Approves Opdivo for Treatment of Bladder Cancer (February 16, 2017)

The US Food and Drug Administration (FDA) today approved Opdivo, (nivolumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed during a period of up to 1 year after first-line platinum-containing... Continue Reading

Tecentriq® Approved for Bladder Cancer (June 8, 2016)

The United States Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) for the treatment of bladder cancer. Atezolizumab is an immunotherapy agent referred to as a PD-1/PD-L1 inhibitor, and is the first agent in this class to be approved... Continue Reading

Tecentriq® Effective as Initial Therapy in Advanced Bladder Cancer (June 8, 2016)

The immunotherapy agent Tecentriq® (atezolizumab) provides anti-cancer activity when used as initial therapy among patients with advanced bladder cancer who are not able to tolerate standard therapy. These results were recently presented at the 2016... Continue Reading

Radiotherapy for Prostate Cancer Increases Risk of Secondary Cancers (March 14, 2016)

Patients with prostate cancer considering radiation therapy should now be informed that radiotherapy raises the risk of developing a secondary cancer. Prostate cancer patients who undergo radiotherapy raise their risk of getting other cancers by nearly... Continue Reading

Atezolizumab Provides Long-Lasting Anti-Cancer Responses in Advanced Bladder Cancer (January 21, 2016)

The immunotherapeutic agent, atezolizumab, which is still in investigative stages, provides high rates of anti-cancer responses among patients with advanced bladder cancer. These results were recently presented at the 2016 Genitourinary Cancers Symposium... Continue Reading

Chemotherapy after Surgery Appears to Improve Survival in Advanced Bladder Cancer (March 31, 2015)

Patients with advanced bladder cancer who receive chemotherapy after surgery to remove the bladder have better overall survival than patients who undergo surgery alone. These findings were presented at the 2015 Genitourinary Cancers Symposium on February... Continue Reading

Votrient® plus Taxol® Promising in Relapsed and Refractory Bladder Cancer (March 30, 2015)

The treatment combination of Votrient® (pazopanib) plus Taxol® (paclitaxel) appears active against bladder cancer that has not responded to or come back after previous therapy. These findings were presented at the 2015 Genitourinary Cancers Symposium... Continue Reading

Cyramza® plus Taxotere® Promising in Advanced Bladder Cancer (March 16, 2015)

The treatment combination of Cyramza® (ramucirumab) plus Taxotere® (docetaxel) appears to extend progression-free survival in patients with advanced bladder cancer that has relapse after previous treatment. These findings were presented at the 2015... Continue Reading

Latest Bladder Cancer News By Stage


Recurrent Bladder Cancer

Votrient® plus Taxol® Promising in Relapsed and Refractory Bladder Cancer (March 30, 2015)

The treatment combination of Votrient® (pazopanib) plus Taxol® (paclitaxel) appears active against bladder cancer that has not responded to or come back after previous therapy. These findings were presented at the 2015 Genitourinary Cancers Symposium... Continue Reading

Cyramza® plus Taxotere® Promising in Advanced Bladder Cancer (March 16, 2015)

The treatment combination of Cyramza® (ramucirumab) plus Taxotere® (docetaxel) appears to extend progression-free survival in patients with advanced bladder cancer that has relapse after previous treatment. These findings were presented at the 2015... Continue Reading

Survival Benefit with Immediate Adjuvant Chemotherapy in Invasive Bladder Cancer (June 23, 2014)

Results from a recent Phase III clinical trial suggest that patients with invasive bladder cancer may benefit from treatment with immediate adjuvant chemotherapy. These finding were presented at the 2014 American Society of Clinical Oncology (ASCO) meeting... Continue Reading

Experimental Drug Shows Promise for Treatment of Metastatic Bladder Cancer (June 12, 2014)

According to results of a Phase I trial presented at the 2014 annual meeting of the American Society of Clinical Oncology, an investigative drug, MPDL3280A, demonstrates promise for the treatment of PD-L1 positive metastatic bladder cancer. Bladder cancer... Continue Reading

Cystoscopy Alone Is the Most Cost-effective Way to Monitor for Recurrence of Bladder Cancer (March 9, 2010)

The addition of a urine test to standard cystoscopy screening in order to monitor for bladder cancer recurrence unnecessarily increases the cost of monitoring as well as the risk for a false-positive result and does not improve tumor detection, according... Continue Reading

More Recurrent Bladder Cancer

Screening/Prevention Bladder Cancer

Radiation for Uterine Cancer May Increase Risk of Bladder Cancer (January 20, 2014)

Radiation therapy used to treat uterine cancer may increase the risk of bladder cancer later in life, according to the results of a study published in BJU International. Uterine (endometrial) cancer is one of the most common gynecologic cancers in women,... Continue Reading

Selenium May Have Protective Effect Against Bladder Cancer (September 16, 2010)

Data from a combined analysis of previous studies suggest that higher levels of selenium are associated with lower risk of bladder cancer. These findings were recently published in the journal Cancer Epidemiology, Biomarkers & Prevention.[1] Each... Continue Reading

Components of Processed Meat May Increase Risk of Bladder Cancer (August 10, 2010)

People who consume a large amount of nitrite and nitrate from processed meat may be at an increased risk for developing bladder cancer, according to a study published in Cancer. Bladder cancer is diagnosed in as many as 60,000 individuals annually in... Continue Reading

Painters May Have Higher Risk of Bladder Cancer (July 29, 2010)

Occupational exposures appear to increase bladder cancer risk in painters, according to a study published in Occupational and Environmental Medicine. Workers in certain occupations may face an increased risk of cancer due to exposures that they encounter... Continue Reading

Exposure to Aromatic Amines Poses Long-term Risk of Bladder Cancer (June 25, 2010)

Workers exposed to aromatic amines continued to experience an increased risk of bladder cancer even 30 years after exposure, according to the results of a follow-up study published in the Journal of the National Cancer Institute.[1] Aromatic amines are... Continue Reading

More Screening/Prevention Bladder Cancer

Stage III Bladder Cancer

Chemotherapy after Surgery Appears to Improve Survival in Advanced Bladder Cancer (March 31, 2015)

Patients with advanced bladder cancer who receive chemotherapy after surgery to remove the bladder have better overall survival than patients who undergo surgery alone. These findings were presented at the 2015 Genitourinary Cancers Symposium on February... Continue Reading

Survival Benefit with Immediate Adjuvant Chemotherapy in Invasive Bladder Cancer (June 23, 2014)

Results from a recent Phase III clinical trial suggest that patients with invasive bladder cancer may benefit from treatment with immediate adjuvant chemotherapy. These finding were presented at the 2014 American Society of Clinical Oncology (ASCO) meeting... Continue Reading

Immediate Cisplatin-Based Chemotherapy Extends Progression-Free Survival in Invasive Bladder Cancer (June 17, 2014)

A report at the 2014 American Society of Clinical Oncologists meeting indicates that immediate use of cisplatin-based chemotherapy offers significant improvement in progression-free survival over deferred treatment in invasive bladder cancer patients.... Continue Reading

More Stage III Bladder Cancer

Stage IV/Metastatic Bladder Cancer

Tecentriq® Approved for Bladder Cancer (June 8, 2016)

The United States Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) for the treatment of bladder cancer. Atezolizumab is an immunotherapy agent referred to as a PD-1/PD-L1 inhibitor, and is the first agent in this class to be approved... Continue Reading

Tecentriq® Effective as Initial Therapy in Advanced Bladder Cancer (June 8, 2016)

The immunotherapy agent Tecentriq® (atezolizumab) provides anti-cancer activity when used as initial therapy among patients with advanced bladder cancer who are not able to tolerate standard therapy. These results were recently presented at the 2016... Continue Reading

Cyramza® plus Taxotere® Promising in Advanced Bladder Cancer (March 16, 2015)

The treatment combination of Cyramza® (ramucirumab) plus Taxotere® (docetaxel) appears to extend progression-free survival in patients with advanced bladder cancer that has relapse after previous treatment. These findings were presented at the 2015... Continue Reading

Survival Benefit with Immediate Adjuvant Chemotherapy in Invasive Bladder Cancer (June 23, 2014)

Results from a recent Phase III clinical trial suggest that patients with invasive bladder cancer may benefit from treatment with immediate adjuvant chemotherapy. These finding were presented at the 2014 American Society of Clinical Oncology (ASCO) meeting... Continue Reading

Experimental Drug Shows Promise for Treatment of Metastatic Bladder Cancer (June 12, 2014)

According to results of a Phase I trial presented at the 2014 annual meeting of the American Society of Clinical Oncology, an investigative drug, MPDL3280A, demonstrates promise for the treatment of PD-L1 positive metastatic bladder cancer. Bladder cancer... Continue Reading

More Stage IV/Metastatic Bladder Cancer

Stages 0-I Bladder Cancer

Studies Evaluate Robot Assisted Cystectomy Treatment of Bladder Cancer (July 29, 2014)

The bladder is a hollow organ located in the pelvis. Its primary function is to store urine. The bladder has a muscular wall that allows it to get larger and smaller as urine is stored or emptied. Bladder cancer is diagnosed in roughly 50,000 men and... Continue Reading

More Stages 0-I Bladder Cancer

Stages II-III Bladder Cancer

Votrient® plus Taxol® Promising in Relapsed and Refractory Bladder Cancer (March 30, 2015)

The treatment combination of Votrient® (pazopanib) plus Taxol® (paclitaxel) appears active against bladder cancer that has not responded to or come back after previous therapy. These findings were presented at the 2015 Genitourinary Cancers Symposium... Continue Reading

Studies Evaluate Robot Assisted Cystectomy Treatment of Bladder Cancer (July 29, 2014)

The bladder is a hollow organ located in the pelvis. Its primary function is to store urine. The bladder has a muscular wall that allows it to get larger and smaller as urine is stored or emptied. Bladder cancer is diagnosed in roughly 50,000 men and... Continue Reading

Survival Benefit with Immediate Adjuvant Chemotherapy in Invasive Bladder Cancer (June 23, 2014)

Results from a recent Phase III clinical trial suggest that patients with invasive bladder cancer may benefit from treatment with immediate adjuvant chemotherapy. These finding were presented at the 2014 American Society of Clinical Oncology (ASCO) meeting... Continue Reading

Immediate Cisplatin-Based Chemotherapy Extends Progression-Free Survival in Invasive Bladder Cancer (June 17, 2014)

A report at the 2014 American Society of Clinical Oncologists meeting indicates that immediate use of cisplatin-based chemotherapy offers significant improvement in progression-free survival over deferred treatment in invasive bladder cancer patients.... Continue Reading

Study Evaluates Incidence of Lymphedema Resulting from Cancer Treatment (August 9, 2010)

A systematic review of 47 studies evaluating treatment for melanoma, head and neck cancer, genitourinary cancers, gynecologic cancers, and sarcoma indicates that lymphedema is a common side effect of treatment for these diseases. These findings were recently... Continue Reading

More Stages II-III Bladder Cancer